Indication

Disseminated blastomycosis

Disseminated blastomycosis is an invasive, systemic fungal infection caused by the dimorphic pathogens *Blastomyces dermatitidis* or *Blastomyces gilchristii*. Read more about Disseminated blastomycosis

1 drugs 1 manufacturers

Drugs that treat it

Common Disseminated blastomycosis therapies.

Showing 1–1 of 1 drugs

Sort

TOLSURA (itraconazole)

ANTIFUNGALS-SYSTEMIC·CHRONIC PULMONARY HISTOPLASMOSIS·+5

LIBERTAS PHARMA

Filter & compare in the drug finder →Opens the drug finder with Disseminated blastomycosis preselected.

News & literature

Coming soon

Related codes

Coming soon

About Disseminated blastomycosis.

Disseminated blastomycosis is an invasive, systemic fungal infection caused by the dimorphic pathogens *Blastomyces dermatitidis* or *Blastomyces gilchristii*.

It develops when inhaled fungal conidia convert to parasitic yeast forms within the lungs and subsequently undergo hematogenous or lymphatic spread beyond the pulmonary parenchyma.

While both immunocompetent and immunocompromised individuals can be affected, immunocompromised hosts face a markedly higher risk of severe, fulminant disease.

Clinically and pathophysiologically, it is defined by multiorgan involvement and suppurative or granulomatous lesions, most frequently manifesting as verrucous or ulcerative cutaneous plaques, osteomyelitis, septic arthritis, and less commonly genitourinary or central nervous system infections.

cdc.gov
Disseminated blastomycosis is an invasive, systemic fungal infection caused by the dimorphic pathogens *Blastomyces dermatitidis* or *Blastomyces gilchristii* It develops when inhaled fungal conidia convert to parasitic yeast forms within the lungs and subsequently undergo hematogenous or lymphatic spread beyond the pulmonary parenchyma While both immunocompetent and immunocompromised individuals can be affected, immunocompromised hosts face a markedly higher risk of severe, fulminant disease
cdc.gov
Disseminated blastomycosis is an invasive, systemic fungal infection caused by the dimorphic pathogens *Blastomyces dermatitidis* or *Blastomyces gilchristii*
nih.gov
It develops when inhaled fungal conidia convert to parasitic yeast forms within the lungs and subsequently undergo hematogenous or lymphatic spread beyond the pulmonary parenchyma
nih.gov
It develops when inhaled fungal conidia convert to parasitic yeast forms within the lungs and subsequently undergo hematogenous or lymphatic spread beyond the pulmonary parenchyma Clinically and pathophysiologically, it is defined by multiorgan involvement and suppurative or granulomatous lesions, most frequently manifesting as verrucous or ulcerative cutaneous plaques, osteomyelitis, septic arthritis, and less commonly genitourinary or central nervous system infections
nih.gov
While both immunocompetent and immunocompromised individuals can be affected, immunocompromised hosts face a markedly higher risk of severe, fulminant disease Clinically and pathophysiologically, it is defined by multiorgan involvement and suppurative or granulomatous lesions, most frequently manifesting as verrucous or ulcerative cutaneous plaques, osteomyelitis, septic arthritis, and less commonly genitourinary or central nervous system infections
nih.gov
Clinically and pathophysiologically, it is defined by multiorgan involvement and suppurative or granulomatous lesions, most frequently manifesting as verrucous or ulcerative cutaneous plaques, osteomyelitis, septic arthritis, and less commonly genitourinary or central nervous system infections

Personalize your experience

Follow Disseminated blastomycosis and get updates as they land.

Create a free account

Already a member? Sign in

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it